News
The Advantages of Custom Thrombosis and Hemostasis Assays in Early Therapeutic Development
If you are here, you likely know that developing a new medicine is a massive and expensive undertaking. Therapeutics primarily fail because the treatment is not clinically meaningful or they are not safe. It is never too soon to start thinking about establishing an early-stage hematology testing program to evaluate a candidates’ potential side effects or MOA. Investing in mechanistic or exploratory hematology-based assays can increase the chances for regulatory clearance, save money and time, and most importantly, identify patients most likely to respond to drug therapy.
Our Global Chief Scientific Officer, Lisa K Jennings, PhD, an internationally recognized KOL in hematology, brings over three decades of experience to this live seminar and Q&A.
In this live seminar, you will learn about:
- The value of adding custom hematology-based assays to your R&D program
- Hematology-based assays readout options
- Assay Development vs. Tech Transfer
- What standards to look for regarding quality, flexibility, and reliability
- The current and evolving role in determining MOAs and pathways
Who should attend:
- Director of Translational Research
- Director of Research and Development
- Chief Scientific Officers
- Head of Biomarker Development
- Research Operations
- Clinical Research Associates
- Outsourcing/Vendor Management
Mark your calendar for this insightful session and register today!
